ArtVentive Medical has received US Food and Drug Administration (FDA) clearance for the Endoluminal Occlusion System (EOS). Designed for use in the peripheral vasculature, the EOS offers immediate, complete and total occlusion in arterial and venous settings.
“I see the EOS device as a potential game changer for physicians and their patients,” says Anthony Venbrux, interventional radiologist at The George Washington University Hospital in Washington, DC. “In my experience with the device, it has shown immediate and complete vascular occlusion upon deployment. The use of this new endovascular technology assures the operator that they have stopped blood flow at the treatment site. This creates an opportunity for shorter procedure times and less radiation exposure to patients and staff in addition to lower medical costs.”
“We are excited to introduce the EOS device into the US market,” said Leon Rudakov, president of ArtVentive. “We are expanding our case experience in Europe and anticipate further positive acceptance in the USA and global markets.”
